YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Parabilis Medicines, Inc. CAMBRIDGE, Mass., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines (Nasdaq: PBLS), a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for patients with serious diseases b…
Parabilis Medicines, Inc. Advanced zolucatetide across multiple Wnt/β-catenin-driven diseases, including progress toward planned Phase 3 registrational trial in desmoid tumors Announced strategic research collaboration with Regeneron to de…
Positive readouts in cancer and cardiac drug trials could keep the rally going. Sizing up the stakes for Merck, Moderna, Summit Therapeutics, and more. Continue Reading
(RTTNews) - The following biotech stocks reached a 52-week high on August 4, 2026, driven by key catalysts like positive quarterly results or certain regulatory milestones. UFP Technologies Inc. (UFPT) UFP Technologies is a contract develo…
Quick Read T-Mobile (TMUS) and Gilead Sciences (GILD) both earned Buy upgrades Monday, with Bank of America and HSBC setting targets of $220 and $155 respectively. Pfizer (PFE) and Datadog (DDOG) both took ratings cuts Monday, though Berns…
Key Points Parabilis saw its shares rise by more than SpaceX's shares did after its IPO. That doesn't mean it's guaranteed to succeed. If anything, the nature of its platform technology means that it has many big challenges ahead.10 stocks…
Key Points Director Alan Sebulsky acquired 17,500 shares for $474,000, based on a weighted average purchase price of $27.06 per share. This activity increased his ownership to 30,000 shares, held through an entity he controls. He also has…
Just a few days after a well-received initial public offering, a director of drug developer Parabilis Medicines (NASDAQ:PBLS) bought shares in the open market. Director Alan Sebulsky disclosed the purchase of 17,500 shares in multiple open…
Key Points SpaceX rose $75 billion last week in the world’s biggest-ever IPO. The company is heading for “a significant growth phase,” chief Elon Musk says.These 10 stocks could mint the next wave of millionaires › SpaceX (NASDAQ: SPCX) ad…
Wall Street traded higher on Friday as investors focused on the highly anticipated public debut of SpaceX, with enthusiasm surrounding the offering helping support gains across major U.S. equity indexes. The blue-chip Dow Jones Industrial…
This year is turning out to be a massive one for initial public offerings, with Cerebras Systems delivering the biggest so far and SpaceX on track to launch the largest ever. On top of that, Anthropic and OpenAI recently filed confidential…
Key Points Parabilis and another recent IPO stock each raised more than Moderna -- which had previously been the biggest biotech IPO. Parabilis’ technology could be a game changer and potentially used across treatment areas.These 10 stocks…
Parabilis Medicines (PBLS) had a thunderous debut on Nasdaq this week — opening at a little over $33, up an exciting 67% versus the $20 initial public offering (IPO) price. PBLS raised some $670 million through the IPO, the largest haul ev…
(RTTNews) - Today's top biotech gainers include Parabilis, following a strong debut on its first day of trading; Shoulder Innovations, which recently issued a rosy outlook for the year; and Clover Health, which won a legal victory in its d…
This article first appeared on GuruFocus. Parabilis Medicines is coming to market with serious momentum behind it. The clinical-stage cancer drug developer raised nearly $745 million through an upsized US initial public offering and a priv…
[Wooden blocks with the word IPO and virtual stock graph. Initial Public Offering or stock launch concept.] fadfebrian Parabilis Medicines (PBLS [https://seekingalpha.com/symbol/PBLS]) climbed more than 45% in its first trading session on…
Parabilis Medicines priced its initial public offering at $20 per share on Tuesday, raising $670 million in what Fierce Biotech called the largest IPO in biotech history. A total of 33.5 million shares were sold in the offering, with tradi…
Parabilis Medicines has secured the largest initial public offering (IPO) in biotech history, suggesting that an uptick of upsized public listings in the sector shows no signs of slowing. Parabilis, a US biotech specialising in cancer ther…
[IPO and Stock Market Analysis] bymuratdeniz * Parabilis Medicines (PBLS [https://seekingalpha.com/symbol/PBLS]) priced [https://seekingalpha.com/pr/20546168-parabilis-medicines-announces-pricing-of-upsized-initial-public-offering] its ups…
CAMBRIDGE, Mass., June 09, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines, Inc. (Nasdaq: PBLS) (“Parabilis”), a clinical-stage biopharmaceutical company built to develop transformative medicines addressing some of the most consequential, yet…